Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age

NCT07003984 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT07003984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07003984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 1 to <12 Years of Age
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 5, 2025
Completion date
September 30, 2028
Enrollment
720 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus